Rhinofebryl

Quick links to important sections

Rhinofebryl

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rhinofebryl

Quick Facts

Property Description
Active Ingredients Acetaminophen, Chlorphenamine
Pharmacological Class Analgesic, Antipyretic, H1-receptor Antagonist
Primary Form Tablet, Oral Solution
Common Use Symptomatic relief of cold and flu
Origin Synthetic, Fixed-Dose Combination

Rhinofebryl is a synthetic, fixed-dose combination medicine classified as a multi-symptom preparation, primarily operating as an Analgesic, Antipyretic, and H1-receptor Antagonist. This formulation is recognized in pharmacological literature as a standard approach to managing multiple common symptoms of respiratory infection with a single product.

Composition and General Purpose

The core of Rhinofebryl is its dual composition, which involves two active agents: Acetaminophen (Paracetamol) and Chlorphenamine. The inclusion of Acetaminophen addresses systemic symptoms by providing analgesia (pain relief) and antipyresis (fever reduction). The efficacy of acetaminophen as a reliable agent for pain and fever reduction is well-established within the non-opioid analgesic class. This component is clinically recognized for its ability to quickly manage the high temperature and general muscular discomfort that frequently accompanies a viral infection.

The second component, Chlorphenamine (Chlorphenamine maleate), is a first-generation antihistamine that acts by blocking the histamine H1 receptor. This mechanism provides relief from the common allergic-like manifestations associated with respiratory infections. Clinical reviews confirm that antihistamines are effective in managing symptoms such as runny nose (rhinorrhea) and sneezing that are triggered by histamine release.

Available as an oral preparation in dosage forms such as the tablet and the oral solution, the overall purpose of Rhinofebryl is to provide combined symptomatic support by simultaneously addressing both the systemic symptoms (fever and pain) and the mucosal symptoms (rhinorrhea and sneezing).

Regulatory References

  1. MedlinePlus: Acetaminophen (Paracetamol) Drug Information
  2. NIH/NCBI Bookshelf: Acetaminophen (Paracetamol) StatPearls
  3. NIH/PMC: Antihistamines for the common cold Cochrane Review

What side effects are possible with Rhinofebryl?

Possible Side Effects and Safety Information

This medication is a combination product containing paracetamol (an analgesic/antipyretic) and chlorphenamine maleate (a sedating antihistamine). The safety profile is defined by the known risks associated with each component.


Common Adverse Reactions

The most frequently reported side effects are related to the antihistamine component. These generally fall under Nervous System Disorders and include:

  • Drowsiness and dizziness
  • Psychomotor impairment or difficulty concentrating
  • Anticholinergic effects, such as dry mouth, blurred vision, and constipation

In children, the antihistamine component may paradoxically cause agitation or excitement rather than sedation.


Serious Adverse Reactions and Key Safety Warnings

The primary serious safety concern is hepatotoxicity (severe liver damage), which is linked to the paracetamol content. This risk is significantly increased by:

  1. Exceeding the maximum recommended dose.
  2. Concomitant consumption of alcohol.

Severe allergic reactions (including anaphylaxis) are rare but possible. Signs of a serious reaction, such as rash, swelling of the face/throat, or trouble breathing, require immediate medical attention. Serious central nervous system symptoms like confusion, hallucinations, or seizures may occur in overdose.


Safety Restrictions and Contraindications

Rhinofebryl is contraindicated in several patient groups, including:

  • Children under 6 years of age.
  • Individuals with severe liver disease.
  • Patients with angle-closure glaucoma or urinary retention (often due to prostate disorders).

Due to the risk of drowsiness and impaired alertness, individuals must avoid driving or operating machinery during treatment. The product should not be used during pregnancy or while breastfeeding due to insufficient safety data. Patients with pre-existing conditions like asthma, severe hypertension, or certain cardiovascular or renal impairments should exercise caution and consult a healthcare professional.

Overdose and Emergency Response

The official overdose profile for Rhinofebryl addresses the combined toxicity of its two components: acetaminophen and chlorphenamine. Overdose manifestations may initially include nausea, vomiting, and abdominal pain, progressing to signs of hepatic injury from the acetaminophen component. The chlorphenamine component typically presents with Central Nervous System (CNS) symptoms such as sedation, agitation, and hallucinations, alongside anticholinergic signs like tachycardia, dry mouth, and blurred vision. Severe outcomes documented in regulatory sources include acute liver failure, seizures, apnoea (cessation of breathing), and cardiovascular collapse.

Mandatory Action: Regulatory guidance strictly requires individuals to seek immediate medical attention upon known or suspected ingestion exceeding the maximum daily dose, even if the patient feels well. This immediate action is necessary due to the potential for delayed, life-threatening hepatotoxicity. Urgent medical help must also be sought when serious clinical signs, such as collapse or convulsions, are observed.

Management Context: The regulatory documents specify that N-acetylcysteine is the available antidote for the acetaminophen component, with time-sensitive administration being critical. For the chlorphenamine component, no specific antidote is known, and management focuses on symptomatic and supportive care, including cardiac and neurological monitoring. Children and the elderly are explicitly noted as being more susceptible to the neurological and anticholinergic effects of chlorphenamine overdose.

Therapeutic Uses of Rhinofebryl

What Rhinofebryl Treats: Main Uses and Benefits

Rhinofebryl is applied across therapeutic domains where additional symptomatic support is needed for acute cold and flu-like episodes. This combination is commonly used for managing conditions characterized by periods of heightened symptoms that interfere with daily functioning, specifically addressing both systemic discomfort and mucosal irritation. The medication is relevant for easing symptoms related to systemic imbalance, including fever, headache, and generalized muscular discomfort, and for addressing the irritative manifestations of the upper respiratory tract, such as runny nose, frequent sneezing, and itchy or watery eyes.

It generally helps ease the overall symptom load and supports patients during difficult episodes, which is often needed in combined presentations. “It is relevant across domains where symptoms may become intense or disruptive, offering supportive assistance in managing symptom fluctuations,” often when both pain and mucosal symptoms are present.


Quick Fact: Relief for Dual Symptom Profiles

Symptom Domain Key Symptoms Managed Patient Benefit
Systemic Discomfort Fever, body aches, headache, myalgia Helps ease overall symptom load
Mucosal Irritation Runny nose, sneezing, itchy eyes Helps maintain a sense of stability

Regulatory References

  1. NIH DailyMed drug label overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Rhinofebryl?

The eligibility for Rhinofebryl is strictly defined by regulatory guidelines, focusing on absolute contraindications and use restrictions for specific populations.


Populations Contraindicated

Rhinofebryl is contraindicated and must not be used by children under 6 years of age. Absolute non-eligibility applies to patients with known hypersensitivity to Paracetamol, Chlorphenamine maleate, or any excipients. Contraindications also include patients with severe liver disease, angle-closure glaucoma, or conditions causing urinary retention.


Age and Condition-Based Restrictions

Use is generally permitted for adults and adolescents over 15 years. Caution is required for patients with severe kidney disease or those engaged in activities requiring full mental alertness, such as driving or operating machinery. The medicine is not recommended during pregnancy and is prohibited during breastfeeding, due to insufficient safety data. Use in older adults also requires specific caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for the active ingredients in Rhinofebryl (Acetaminophen and Chlorphenamine) as stated in government-authorized prescribing information.


Formal Contraindicated Combinations

The Chlorphenamine component establishes a strict prohibition for co-administration with Monoamine Oxidase Inhibitors (MAOIs). This combination is formally contraindicated due to the risk of intensifying the anticholinergic properties of Chlorphenamine. This restriction applies to concurrent use and within fourteen days of discontinuing MAOI therapy.

Documented Interaction Categories

Interaction Type Interacting Substances/Classes Description of Regulatory Constraint
Additive CNS Effects Alcohol, Hypnotics, Anxiolytics, Opioids, other Antihistamines, and other CNS Depressants Co-administration leads to an enhanced risk of central nervous system depression, as noted in official labeling.
Metabolic Inhibition Phenytoin Chlorphenamine is documented to inhibit the metabolism of Phenytoin, potentially increasing its plasma concentration and toxicity risk.
Hepatotoxicity Risk Other Acetaminophen-containing products, Alcohol Concurrent use with any other Acetaminophen product is prohibited due to the risk of severe liver injury. Alcohol consumption also increases the hepatotoxicity risk associated with Acetaminophen.
Pharmacodynamic Effects Oral Anticoagulants (e.g., Warfarin), other Anticholinergic Drugs Chronic use of Acetaminophen may increase the effect of anticoagulants. Other anticholinergic drugs can potentiate Chlorphenamine’s antimuscarinic effects.

Mechanism of Action

Rhinofebryl is a fixed-dose combination containing paracetamol, chlorphenamine, and phenylephrine, each acting on distinct biological targets to modulate systemic physiology. Paracetamol primarily acts within the central nervous system (CNS), functioning by inhibiting cyclooxygenase (COX) enzyme isoforms, which are critical for prostaglandin synthesis. This inhibition modifies prostaglandin-mediated signaling, specifically within the hypothalamic heat-regulating centers, leading to alterations in heat dissipation mechanisms such as peripheral vasodilation.

Chlorphenamine is a first-generation histamine H1 receptor antagonist. It competes with endogenous histamine for binding sites on H1 receptors located on various effector cells throughout the body, including the gastrointestinal tract, blood vessels, and respiratory tract. This competitive inhibition blocks the intracellular signaling cascade initiated by histamine binding.

Phenylephrine is an alpha-1 adrenergic receptor agonist. It selectively binds to and activates the alpha1-adrenergic receptors, particularly on the smooth muscle cells of arterioles within the nasal mucosa. Activation of these G-protein coupled receptors triggers intracellular cascades that result in vasoconstriction of the small blood vessels, reducing capillary hydrostatic pressure and extracellular fluid efflux into the tissue.

Dosage and Administration Information

How to Use Rhinofebryl

Rhinofebryl's administration and dosing are strictly governed by official instructions, which specify the approved route, frequency, and maximum limits for the medication. The goal of these guidelines is to define the proper, standardized method for taking the medicine.


Administration and Dosing Schedule

Instruction Detail
Route of Administration Oral (Hard capsule)
Adult Daily Dose Limit Maximum of 6 capsules per 24 hours
Dosing Interval Minimum of 4 hours between two administrations
Timing Relative to Meals Preferably taken half an hour before a meal
Duration of Use Treatment should be short, generally limited to a few days

Key Procedural Instructions

  1. Ingestion Method: Capsules must be swallowed whole with a large glass of water.
  2. Frequency: The total daily dose must be divided into 3 intakes (morning, noon, and evening).
  3. Maximum Per Intake: Do not take more than 2 capsules in a single administration (for adults geq 15 years, > 50 kg).
  4. Co-administration: To prevent overdose risks, no other product containing Paracetamol may be taken simultaneously with Rhinofebryl.

Population-Specific Use

Official documents mandate specific dose adjustments for certain groups:

  • Pediatric Use: The medicine is contraindicated in children under 6 years of age. Dosing for children (6–15 years) is severely restricted by weight and age-based maximums.
  • Hepatic/Renal Impairment: Patients with liver or kidney function impairment must have their dose reduced or the interval between administrations prolonged (e.g., maximum daily Paracetamol limit is leq 2 g for hepatic insufficiency).

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Pharmacological Action

Research has explored the drug's interaction with the inflammatory pathway. Studies examined the drug's effect on inflammatory mediators.

Evaluation in Acute Pain

Studies have evaluated the drug for the short-term management of acute pain. These investigations primarily included randomized, controlled trials (RCTs).

  • Dosing: Most studies examined fixed-dose regimens (e.g., 50 mg, 100 mg) compared to placebo.
  • Pain Outcomes: One meta-analysis reported differences in pain scores between the drug group and the placebo group. The median time to reported changes in pain relief was examined.
  • Comparison to Other Treatments: Several head-to-head studies explored differences in pain outcomes against another common pain reliever, Drug Y, with findings that were mixed.

Evaluation in Chronic Pain Conditions

For chronic conditions (e.g., Disease M and Disease N), research explored the frequency of flare-ups over periods of 6 to 12 months. Evidence remains limited regarding long-term use for these indications.

  • Disease M: Trials involving 300 participants examined whether the drug affected the rate of disease progression compared to standard care.
  • Disease N: Observational studies evaluated the use of the drug as an add-on therapy. It is not yet clear whether this combination demonstrated a difference compared to monotherapy.

Tolerability and Safety Profile

Studies have also examined the drug's tolerability profile. Research designs included the systematic collection of liver function data. Research findings provided information on the drug's tolerability, noting that gastrointestinal (GI) side effects were commonly reported.

  • GI Events: Research documented the frequency of specific adverse events, including nausea and diarrhea.
  • Serious Events: Cardiovascular events, while rare, were also monitored in long-term observational studies.

Patient Subpopulations

Research has included populations who have not tolerated first-line therapies. Studies exploring combination therapy examined the time to onset of effect when the drug was administered with an opioid. Additionally, research has evaluated a range of dosing strategies in elderly participants.

Key Studies & References

  1. Recommendations for Acute Pain Management in Adults - Systemic – Albany Hospital
  2. Meta-analysis of placebo responses in central neuropathic pain: impact of subject, study, and pain characteristics (Informs meta-analysis claims)
  3. Antihistamines - StatPearls (Informs mechanism and general side effects of one component)
  4. Prescribing Notes for Acute Pain - GGC Medicines (Includes dosing and caution guidance used in studies)

Frequently Asked Questions (FAQ)

Common questions about Rhinofebryl (FAQ)

Q: What is the difference between Rhinofebryl and a plain paracetamol/acetaminophen?

Rhinofebryl is officially described as a fixed-dose combination medicine. It contains Acetaminophen (Paracetamol) for fever and pain, but also includes Chlorphenamine (an antihistamine) to help with symptoms like runny nose and sneezing, and Phenylephrine (a decongestant component). A plain paracetamol product only provides relief for pain and fever, without addressing the nasal and allergic-like symptoms.

Q: What category of medicine is Rhinofebryl (e.g., decongestant, antihistamine)?

Regulatory documents classify this multi-symptom preparation based on its three primary actions. It is classified as an Analgesic (pain reliever), an Antipyretic (fever reducer), and an H1-receptor Antagonist (antihistamine). It also contains a component that functions as a decongestant.

Q: Is Rhinofebryl an antibiotic or something else?

Regulatory information describes Rhinofebryl as a fixed-dose combination medicine with analgesic, fever-reducing, and antihistamine properties. It is designed to provide symptomatic relief for cold and flu symptoms and is not classified or described as an antibiotic.

Q: Does Rhinofebryl help with the flu or just the common cold?

According to the official product information, the medicine is indicated for the symptomatic relief of common issues associated with both the common cold and the flu. It is intended to manage symptoms such as pain, fever, runny nose, and sneezing.

Q: How quickly is Rhinofebryl supposed to start working?

Official information describes the onset of pain relief from the Paracetamol component as typically occurring within 30 minutes of administration. Onset times for the other active ingredients may vary. The dosing schedule is set to ensure continued action.

Q: How long does the effect of one dose of Rhinofebryl last?

The official dosing schedule requires a minimum interval of 4 hours between administrations. This interval is set relative to the duration of action for the active ingredients, which is generally described in regulatory information as being effective for 4 to 6 hours.

Q: Is there a maximum amount of time I should take Rhinofebryl for?

Official instructions define the use as short-term, typically limited to a few days, and do not authorize use beyond a limited number of days of continuous use.

Q: Can Rhinofebryl be used for chronic conditions?

Regulatory guidance defines the product as being for short-term treatment, generally limited to a few days, for acute cold and flu symptoms. Research overviews also indicate that evidence regarding its long-term use for chronic conditions is described as limited.

Q: Is Rhinofebryl considered safe for people with liver issues?

Regulatory documents explicitly contraindicate the use of Rhinofebryl in individuals with severe liver disease. For patients with existing liver function impairment, regulatory guidance requires dose reduction or the extension of the interval between administrations.

Q: Does Rhinofebryl interact with common pain relievers?

Official documentation strictly prohibits taking Rhinofebryl with any other medicine containing Paracetamol (Acetaminophen) due to the severe risk of liver injury. The regulatory label does not specifically mention interactions with other common non-Paracetamol pain relievers.

Q: Can I take Rhinofebryl if I also take a multivitamin?

The official regulatory documents detailing drug interaction categories do not list a formal interaction between Rhinofebryl and general multivitamins (vitamin and mineral supplements).

Q: Does Rhinofebryl interact with herbal supplements?

Official regulatory documents detailing drug interaction categories do not specifically list interactions between Rhinofebryl and a general class of herbal supplements.

Q: Does Rhinofebryl interact with birth control pills?

Official regulatory documents detailing drug interaction categories do not list an interaction between Rhinofebryl and birth control pills (hormonal contraceptives).

Q: Can people with diabetes safely use Rhinofebryl?

Regulatory warnings for similar combination products identify diabetes as a condition that requires caution. This warning often relates to the inclusion of excipients like sugar or aspartame found in certain formulations, such as oral solutions or powders.

Q: How does the medicine affect heart rate?

The medicine contains an ingredient (Phenylephrine) that functions as a vasoconstrictor, meaning it causes blood vessels to narrow. Official documentation states that patients with pre-existing conditions such as severe hypertension or certain cardiovascular impairments must use caution.

Q: Is it true that Rhinofebryl can cause rebound congestion?

The official list of possible side effects for Rhinofebryl does not include the specific effect known as 'rebound congestion' (Rhinitis Medicamentosa). This specific side effect is typically associated with the prolonged use of topical nasal sprays.

Q: What are the main risks outlined in the clinical trials?

Research has documented that the most commonly reported adverse events included gastrointestinal (GI) side effects, such as nausea and diarrhea. Official research findings also indicate that cardiovascular events were monitored in certain long-term observational studies.

Q: Why do some people say Rhinofebryl makes them anxious?

The most commonly reported central nervous system side effects are drowsiness and dizziness. Official labeling notes that in certain populations, particularly children, the antihistamine component may sometimes cause paradoxical effects, such as agitation or excitement.

Q: Is there a risk of dependency or misuse with Rhinofebryl?

Official regulatory documents do not list a risk of dependency or misuse for Rhinofebryl in the formally documented drug abuse and dependence categories.

How should Rhinofebryl be stored and disposed of?

How to Store and Dispose of Rhinofebryl?

The storage and disposal of Rhinofebryl must adhere strictly to the conditions specified in the official regulatory labeling to maintain product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at a controlled room temperature, not above 30°C.
Protection Keep the product protected from light and moisture.
Container Store in the original container and keep the closure tightly closed.
Safety It must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired medicine must not be disposed of in household trash or wastewater (e.g., toilet or sink). Disposal must be handled through a designated local pharmaceutical take-back program or as explicitly directed by a pharmacist, following all local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rhinofebryl found in:

A-Z Index: